If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
PHILADELPHIA, Nov. 28, 2008 — (HSMN NewsFeed) — Hemispherx Biopharma, Inc. (AMEX:HEB ), a Philadelphia-based biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disord…
Biopharmaceuticals, Personnel
Hemispherx Biopharma
Posts from ‘November, 2008’
Attorney Thomas Equels Elected to Hemispherx Biopharma Board of Directors
Hemispherx Biopharma Introduces Expense Reduction Program
Clinical, Regulatory, Manufacturing Operations Remain Intact PHILADELPHIA, Nov. 28, 2008 — (HSMN NewsFeed) — Hemispherx Biopharma, Inc. (AMEX:HEB ) announced today a series of steps to reduce expenses. As Hemispherx Biopharma continues to strive to …
Biopharmaceuticals
Hemispherx Biopharma
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Resubmission to FDA Planned for First Half of 2009 with Additional Data INDIANAPOLIS, Nov. 28 (HSMN NewsFeed) — Eli Lilly and Company (NYSE: LLY ) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (…
Biopharmaceuticals
Eli Lilly, Cymbalta, duloxetine
European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
CORK, Ireland, November 27 (HSMN NewsFeed) — The Committee for Human Medicinal Products (CHMP) has issued a positive opinion recommending approval for once-daily dosing of 800 mg PREZISTA® (darunavir) with low-dose ritonavir as part of combination t…
Biopharmaceuticals, HIV/AIDS, Regulatory
Tibotec Pharmaceuticals, Janssen-Cilag, PREZISTA, darunavir
Siemens Introduces New Standard of Care for Breast Ultrasound
Increased information density, automation and intelligent clinical applications take workflow efficiency in ultrasound to an all new level
CHICAGO, Ill., Nov. 26 (HSMN NewsFeed) — Siemens Healthcare (www.siemens.com/healthcare) highlights the ACUSON …
Devices, Radiology, Oncology
Siemens Healthcare, ACUSON, ultrasound, breast ultrasound
Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
FRAZER, Pa. and PHILADELPHIA, Nov. 26 (HSMN NewsFeed) — Cephalon, Inc. (Nasdaq: CEPH ) and Eurand, Inc. (Nasdaq: EURX ) today announced that they have filed a lawsuit in U.S. District Court in Delaware against Mylan Pharmaceuticals, Inc. and its subsidi…
Biopharmaceuticals, Generics, Litigation
Cephalon, Eurand, Mylan Pharmaceuticals, Barr Pharmaceuticals, cyclobenzaprine
Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
MIAMI, Nov. 26 (HSMN NewsFeed) — Thomas K. Equels, President and Managing Director of the Equels Law Firm, has been elected to the board of directors for Hemispherx BioPharma, Inc. (Amex: HEB ), a Philadelphia-based biopharmaceutical company engaged in …
Biopharmaceuticals, Personnel
Hemispherx BioPharma, Equels Law Firm
PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
Study Expanded to 406 Subjects
FRANKLIN, Mass., Nov. 26 (HSMN NewsFeed) — PLC Systems Inc. (OTC Bulletin Board: PLCSF ) announced today that it has received full approval from the U.S. Food and Drug Administration (FDA) for its U.S. pivotal trial to …
Devices, Interventional, FDA
PLC Systems, RenalGuard, Contrast-Induced Nephropathy
Tarceva(R) (erlotinib) Endorsed by the U.K.’s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
MELVILLE, New York, Nov 26, 2008–(HSMN NewsFeed)–OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) welcomes today’s announcement by the U.K.’s National Institute for Health and Clinical Excellence (NICE) issuing Final Guidance recommending funding by the National…
Biopharmaceuticals, Oncology
OSI Pharmaceuticals, Tarceva, erlotinib, non-small cell lung cancer
MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease
Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies
MUNICH, GERMANY–Nov 26, 2008 — MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at disco…
Biopharmaceuticals
MorphoSys, Galapagos NV, antibodies, arthritis
